ALK and non-small cell lung carcinoma: In a study by Liu et al., NF1 mutations were associated with improved survival in patients receiving immunotherapy, but with poorer outcomes under targeted therapies for patients with EGFR-mutated or ALK-rearranged NSCLC (21).